Materiały źródłowe

• #1 Liposarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Liposarcoma

  Liposarcomas are the most common subtype of soft tissue sarcomas, accounting for at least 20% of all sarcomas in adults. […] However, the liposarcomas do have several forms based on differences in their clinical presentations, severities, genetic abnormalities, prognoses, and preferred treatment regimens. […] While ALT/WDL tumors have very little potential to metastasize, about 10% will convert to an overtly malignant and potentially metastasizing liposarcoma form, dedifferentiated liposarcoma. […] A large randomized controlled trial comparing radiotherapy followed by surgery to surgery alone in ALT/WDL tumors found little difference between the two regimens. […] A review study in 2012 reported the 5 and 10 year survival rates of individuals with ALT/WDL to be 100% and 87%, respectively.

• #2 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #3 Enhancing Liposarcoma Prognosis – A New Predictive Scoring System Inte | CMAR

  https://www.dovepress.com/enhancing-liposarcoma-prognosis–a-new-predictive-scoring-system-integ-peer-reviewed-fulltext-article-CMAR

  Liposarcomas are malignant soft tissue tumours with heterogeneous features and variable prognosis. […] The aim of this study is to analyse the clinical and histopathological features that can influence the prognosis of liposarcoma. […] Therefore, several clinical and histopathological features of liposarcomas, such as tumour location, mitotic index, and tumour necrosis can strongly predict the disease evolution. […] This study focuses on developing a new scoring system that considers histologic subtype, mitotic index, and tumour necrosis as indicators that could predict the risk of disease progression and overall survival in patients with liposarcoma. […] Diagnosing liposarcomas using this two-tiered system could be useful for providing personalized therapy, in order to avoid relapses, metastases and improve the diseases prognosis.

• #4 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #5 Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3398-y

  Grading, LS subtype, negative margins after surgery, metastases and tumour size are independently associated with disease-specific survival, and patients with local recurrence had lower survival rates. […] The survival rates were highly dependent on the grading, LS subtype, negative margins after surgery, metastases and tumour size. […] The existence of metastases and subtype were found to be major single prognostic factors affecting the survival rates. […] Patients with G2 liposarcoma showed significantly worse results in the overall survival than patients with G1 liposarcoma (p = 0.004; Hazard Ratio 8.1; 95%-CI 1.9-34.1) as well as patients with G3 liposarcoma compared to patients with G1 liposarcoma (p = 0.034; Hazard Ratio 4.7; 95%-CI 1.1-19.7). […] Local recurrence in the present study was associated with decreased survival. Patients with local recurrence showed 10- and 5-year survival rates of 86.2% and 49.0%, which was significantly lower than the survival of patients without recurrence (86.7% and 82.9% at 10 and 5 years).

• #6 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #7 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #8 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #9 Liposarcoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1102007-overview

  The prognosis is affected by the type of liposarcoma present. In general, survival for extremity tumors is favorable. […] The well-differentiated type and most myxoid types have favorable prognoses, with 100% and 88% 5-year survival rates, respectively. […] However, these tumors are poorly circumscribed and locally recur after incomplete excision. […] Round-cell and poorly differentiated types have a poor prognosis. Each has a 5-year survival rate of about 50% because they recur locally and tend to metastasize quickly and widely, especially in poorly differentiated liposarcomas. […] Despite high-grade morphology, cutaneous liposarcomas have a favorable clinical prognosis. […] Cutaneous and subcutaneous pleomorphic liposarcomas have a more favorable outcome compared with their deep-seated counterparts, a fact attributable to their small size and superficial location.

• #10 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #11 Liposarcoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1102007-overview

  The prognosis is affected by the type of liposarcoma present. In general, survival for extremity tumors is favorable. […] The well-differentiated type and most myxoid types have favorable prognoses, with 100% and 88% 5-year survival rates, respectively. […] However, these tumors are poorly circumscribed and locally recur after incomplete excision. […] Round-cell and poorly differentiated types have a poor prognosis. Each has a 5-year survival rate of about 50% because they recur locally and tend to metastasize quickly and widely, especially in poorly differentiated liposarcomas. […] Despite high-grade morphology, cutaneous liposarcomas have a favorable clinical prognosis. […] Cutaneous and subcutaneous pleomorphic liposarcomas have a more favorable outcome compared with their deep-seated counterparts, a fact attributable to their small size and superficial location.

• #12 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #13 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #14 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #15 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #16 Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7394804/

  Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. The prognosis of liposarcoma differs greatly by subtype. Metastatic disease was associated with decreased survival across all subtypes and age 35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. The well-differentiated subtype was the most common subtype identified. The lowest median survival was found in the de-differentiated subtype, followed by the pleomorphic, round cell, mixed, well-differentiated, and myxoid subtypes. Kaplan Meier analysis demonstrated that fibroblastic liposarcoma had the highest 5-year survival rate of 94.1%. Rate of 5-year survival was 82.3% for well-differentiated, 76.4% for myxoid, 62.8% for mixed, 54.9% for round cell, 51.2% for pleomorphic, and 49.4% for de-differentiated subtypes. For each subtype, metastatic involvement as well as higher grading are significantly associated with worse outcomes, which corroborates with existing literature. The worst outcomes can be expected among the de-differentiated, pleomorphic, and mixed subtypes.

• #17 Liposarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Liposarcoma

  Retroperitoneal DDL is the most common, surgically unaccessible and serious form of DDL: it has a recurrence rate of 66% and a five-year overall survival rate of 54%. […] A review conducted in 2020 reported median survival times for low histopathological grade and high histopathological grade DDL to be 113 months and 48 months, respectively. […] Overall, the 10-year survival rate of MLS individuals has been 77%, a survival rate appreciably longer than other liposarcoma forms. […] PLS survival rates at 1, 3, and 5 years are reported to be 93%, 75%, and 29%, respectively.

• #18 Liposarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Liposarcoma

  Retroperitoneal DDL is the most common, surgically unaccessible and serious form of DDL: it has a recurrence rate of 66% and a five-year overall survival rate of 54%. […] A review conducted in 2020 reported median survival times for low histopathological grade and high histopathological grade DDL to be 113 months and 48 months, respectively. […] Overall, the 10-year survival rate of MLS individuals has been 77%, a survival rate appreciably longer than other liposarcoma forms. […] PLS survival rates at 1, 3, and 5 years are reported to be 93%, 75%, and 29%, respectively.

• #19 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Background. This study aimed to investigate prognostic factors for patients with myxoid/round-cell liposarcoma (MRCLS), in particular the significance of the round cell component, and to identify metastatic patterns as well as possibly suggest a suitable strategy for followup. […] Overall disease specific survival was 75% at 5 years and 56% at 10 years and was related to the proportion of round cell component. […] The occurrence of any round cell component is the most important adverse prognostic factor for patients with MRCLS; patients with 5% round cell component are at higher risk of local recurrence, metastasis and tumour-related death and should be considered for adjuvant radiotherapy and possibly chemotherapy. […] The most significant factor affecting prognosis was the extent of the round cell component.

• #20 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Background. This study aimed to investigate prognostic factors for patients with myxoid/round-cell liposarcoma (MRCLS), in particular the significance of the round cell component, and to identify metastatic patterns as well as possibly suggest a suitable strategy for followup. […] Overall disease specific survival was 75% at 5 years and 56% at 10 years and was related to the proportion of round cell component. […] The occurrence of any round cell component is the most important adverse prognostic factor for patients with MRCLS; patients with 5% round cell component are at higher risk of local recurrence, metastasis and tumour-related death and should be considered for adjuvant radiotherapy and possibly chemotherapy. […] The most significant factor affecting prognosis was the extent of the round cell component.

• #21 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Assessment of the significance of varying proportions of round cell component revealed that tumours with any round cell component (15% round cell component) carried a worse prognosis than those with no round cell component. […] The survival rate at ten years was 91% for those with no round cell component, 52% for those with up to 5% round cell component, and only 31% for those with 5% round cell component. […] The generally accepted prognostic factors for soft tissue sarcomas are size, grade, and depth of the tumour, along with patient age. […] The risk factors for development of metastases and indeed for overall survival are not surprisingly quite similar but are subtly different from those found in the generality of soft tissue sarcomas. […] We have also confirmed other opinions about the cutoff of 5% round cells as being a watershed between intermediate- and high-risk tumours.

• #22 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Pure myxoid liposarcoma is a relatively low-grade tumour which should be treated surgically with attempts to obtain clear margins of excision. […] Patients with 05% round cell component represent an intermediate-grade tumour with a higher risk of metastatic disease, whilst patients with 5% round cell component must be considered to have a high-grade tumour with a significantly increased risk of both local recurrence and metastases and should be treated with surgical excision with clear margins, radiotherapy, and possibly chemotherapy.

• #23 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  If you have soft tissue sarcoma, you may have questions about your prognosis. A prognosis is the doctors best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors. Only a doctor familiar with your medical history, the type and stage and other features of the cancer, the treatments chosen and the response to treatment can put all of this information together with survival statistics to arrive at a prognosis. […] The size of a soft tissue tumour is an important prognostic factor. Tumours that are 5 cm or smaller have a better prognosis than tumours larger than 5 cm. […] Low-grade soft tissue sarcomas are linked with a better prognosis because they are less likely to spread (metastasize) or come back (recur) than high-grade sarcomas.

• #24 Primary High-Grade Myxoid Liposarcoma of the Extremities: Prognostic Factors and Metastatic Pattern

  https://www.mdpi.com/2072-6694/14/11/2657

  Tumor size is a known prognostic factor for soft tissue sarcomas. According to the published data, the bigger the tumor, the worse the prognosis. […] In our series, we showed that tumor size is a significant risk factor for MFS (log-rank test p = 0.0337, HR = 0.248. 95% CI 0.07–0.84) and DFS (log-rank test p = 0.0199, HR = 0.1773 95% CI: 0.04–0.76). […] We observed a favorable estimated 5-year OS rate of 96%. […] Overall, 5-year PRS was 79% (95% CI: 48–93). […] DFS is a direct measure of clinical benefit. Regarding our series, 74% of patients were DF after primary surgery at the end of the follow-up period, which indicates a generally favorable prognosis associated with this kind of soft tissue sarcoma.

• #25 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  If you have soft tissue sarcoma, you may have questions about your prognosis. A prognosis is the doctors best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors. Only a doctor familiar with your medical history, the type and stage and other features of the cancer, the treatments chosen and the response to treatment can put all of this information together with survival statistics to arrive at a prognosis. […] The size of a soft tissue tumour is an important prognostic factor. Tumours that are 5 cm or smaller have a better prognosis than tumours larger than 5 cm. […] Low-grade soft tissue sarcomas are linked with a better prognosis because they are less likely to spread (metastasize) or come back (recur) than high-grade sarcomas.

• #26 Primary High-Grade Myxoid Liposarcoma of the Extremities: Prognostic Factors and Metastatic Pattern

  https://www.mdpi.com/2072-6694/14/11/2657

  Tumor size is a known prognostic factor for soft tissue sarcomas. According to the published data, the bigger the tumor, the worse the prognosis. […] In our series, we showed that tumor size is a significant risk factor for MFS (log-rank test p = 0.0337, HR = 0.248. 95% CI 0.07–0.84) and DFS (log-rank test p = 0.0199, HR = 0.1773 95% CI: 0.04–0.76). […] We observed a favorable estimated 5-year OS rate of 96%. […] Overall, 5-year PRS was 79% (95% CI: 48–93). […] DFS is a direct measure of clinical benefit. Regarding our series, 74% of patients were DF after primary surgery at the end of the follow-up period, which indicates a generally favorable prognosis associated with this kind of soft tissue sarcoma.

• #27 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  Soft tissue tumours close to the surface of the body (superficial tumours) have a better prognosis than tumours that are growing deep within the body. […] Soft tissue sarcomas of the arms, legs or surface of the trunk of the body usually have a better prognosis than soft tissue sarcomas that start in other parts of the body. […] Some types of soft tissue sarcoma tend to have a worse prognosis, including malignant peripheral nerve sheath tumours (MPNSTs), leiomyosarcoma, desmoplastic small round cell tumours and epithelioid sarcoma. […] The lower the stage of soft tissue sarcoma at diagnosis, the better the prognosis. Stage 4 soft tissue sarcoma (metastatic soft tissue sarcoma) has a poor prognosis. […] If cancer cells are found in the margin (called a positive surgical margin), there is a poorer prognosis compared to when there are no cancer cells in the margin (called a negative surgical margin).

• #28 Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

  https://www.jcancer.org/v07p1174.htm

  Prognosis was worse for the trunk group compared with the extremity group (median disease-free survival [DFS] 3.3 vs. 9.9 years, respectively, P 0.001). […] Median DFS was significantly worse in patients with high grade histology compared to those with low grade histology (16.9% vs. 65.7%, P 0.001). […] Histologic subtype and primary site were independent prognostic factors for curatively resected liposarcoma. A prognostic model for patients with liposarcoma clarified distinct groups of patients with good prognostic discrimination. […] In the multivariate Cox proportional model, histologic subtype and primary site were significant independent risk factors for DFS and OS. […] High-grade liposarcoma was significantly associated with a shorter DFS (hazard ratio [HR] 3.01; 95% confidence interval [CI], 1.82-4.97; P 0.001).

• #29 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  Soft tissue tumours close to the surface of the body (superficial tumours) have a better prognosis than tumours that are growing deep within the body. […] Soft tissue sarcomas of the arms, legs or surface of the trunk of the body usually have a better prognosis than soft tissue sarcomas that start in other parts of the body. […] Some types of soft tissue sarcoma tend to have a worse prognosis, including malignant peripheral nerve sheath tumours (MPNSTs), leiomyosarcoma, desmoplastic small round cell tumours and epithelioid sarcoma. […] The lower the stage of soft tissue sarcoma at diagnosis, the better the prognosis. Stage 4 soft tissue sarcoma (metastatic soft tissue sarcoma) has a poor prognosis. […] If cancer cells are found in the margin (called a positive surgical margin), there is a poorer prognosis compared to when there are no cancer cells in the margin (called a negative surgical margin).

• #30 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  Soft tissue tumours close to the surface of the body (superficial tumours) have a better prognosis than tumours that are growing deep within the body. […] Soft tissue sarcomas of the arms, legs or surface of the trunk of the body usually have a better prognosis than soft tissue sarcomas that start in other parts of the body. […] Some types of soft tissue sarcoma tend to have a worse prognosis, including malignant peripheral nerve sheath tumours (MPNSTs), leiomyosarcoma, desmoplastic small round cell tumours and epithelioid sarcoma. […] The lower the stage of soft tissue sarcoma at diagnosis, the better the prognosis. Stage 4 soft tissue sarcoma (metastatic soft tissue sarcoma) has a poor prognosis. […] If cancer cells are found in the margin (called a positive surgical margin), there is a poorer prognosis compared to when there are no cancer cells in the margin (called a negative surgical margin).

• #31 Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

  https://www.jcancer.org/v07p1174.htm

  Prognosis was worse for the trunk group compared with the extremity group (median disease-free survival [DFS] 3.3 vs. 9.9 years, respectively, P 0.001). […] Median DFS was significantly worse in patients with high grade histology compared to those with low grade histology (16.9% vs. 65.7%, P 0.001). […] Histologic subtype and primary site were independent prognostic factors for curatively resected liposarcoma. A prognostic model for patients with liposarcoma clarified distinct groups of patients with good prognostic discrimination. […] In the multivariate Cox proportional model, histologic subtype and primary site were significant independent risk factors for DFS and OS. […] High-grade liposarcoma was significantly associated with a shorter DFS (hazard ratio [HR] 3.01; 95% confidence interval [CI], 1.82-4.97; P 0.001).

• #32 Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

  https://www.jcancer.org/v07p1174.htm

  Liposarcoma located in the trunk was a significantly poor prognostic factor for DFS (HR 1.80; 95% CI, 1.12-2.89; P = 0.015). […] The prognostic model separated patients into three risk groups with significantly different survival outcomes. The 5-year DFS rates for groups 1, 2, and 3 were 73.6%, 50.8%, and 19.2%, respectively. The 5-year OS rates for groups 1, 2, and 3 were 89.2%, 74.8%, and 41.4%, respectively.

• #33 Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3398-y

  Grading, LS subtype, negative margins after surgery, metastases and tumour size are independently associated with disease-specific survival, and patients with local recurrence had lower survival rates. […] The survival rates were highly dependent on the grading, LS subtype, negative margins after surgery, metastases and tumour size. […] The existence of metastases and subtype were found to be major single prognostic factors affecting the survival rates. […] Patients with G2 liposarcoma showed significantly worse results in the overall survival than patients with G1 liposarcoma (p = 0.004; Hazard Ratio 8.1; 95%-CI 1.9-34.1) as well as patients with G3 liposarcoma compared to patients with G1 liposarcoma (p = 0.034; Hazard Ratio 4.7; 95%-CI 1.1-19.7). […] Local recurrence in the present study was associated with decreased survival. Patients with local recurrence showed 10- and 5-year survival rates of 86.2% and 49.0%, which was significantly lower than the survival of patients without recurrence (86.7% and 82.9% at 10 and 5 years).

• #34 Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

  https://www.jcancer.org/v07p1174.htm

  Prognosis was worse for the trunk group compared with the extremity group (median disease-free survival [DFS] 3.3 vs. 9.9 years, respectively, P 0.001). […] Median DFS was significantly worse in patients with high grade histology compared to those with low grade histology (16.9% vs. 65.7%, P 0.001). […] Histologic subtype and primary site were independent prognostic factors for curatively resected liposarcoma. A prognostic model for patients with liposarcoma clarified distinct groups of patients with good prognostic discrimination. […] In the multivariate Cox proportional model, histologic subtype and primary site were significant independent risk factors for DFS and OS. […] High-grade liposarcoma was significantly associated with a shorter DFS (hazard ratio [HR] 3.01; 95% confidence interval [CI], 1.82-4.97; P 0.001).

• #35 Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3398-y

  Grading, LS subtype, negative margins after surgery, metastases and tumour size are independently associated with disease-specific survival, and patients with local recurrence had lower survival rates. […] The survival rates were highly dependent on the grading, LS subtype, negative margins after surgery, metastases and tumour size. […] The existence of metastases and subtype were found to be major single prognostic factors affecting the survival rates. […] Patients with G2 liposarcoma showed significantly worse results in the overall survival than patients with G1 liposarcoma (p = 0.004; Hazard Ratio 8.1; 95%-CI 1.9-34.1) as well as patients with G3 liposarcoma compared to patients with G1 liposarcoma (p = 0.034; Hazard Ratio 4.7; 95%-CI 1.1-19.7). […] Local recurrence in the present study was associated with decreased survival. Patients with local recurrence showed 10- and 5-year survival rates of 86.2% and 49.0%, which was significantly lower than the survival of patients without recurrence (86.7% and 82.9% at 10 and 5 years).

• #36 Liposarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Liposarcoma

  Retroperitoneal DDL is the most common, surgically unaccessible and serious form of DDL: it has a recurrence rate of 66% and a five-year overall survival rate of 54%. […] A review conducted in 2020 reported median survival times for low histopathological grade and high histopathological grade DDL to be 113 months and 48 months, respectively. […] Overall, the 10-year survival rate of MLS individuals has been 77%, a survival rate appreciably longer than other liposarcoma forms. […] PLS survival rates at 1, 3, and 5 years are reported to be 93%, 75%, and 29%, respectively.

• #37 Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

  https://www.jcancer.org/v07p1174.htm

  Prognosis was worse for the trunk group compared with the extremity group (median disease-free survival [DFS] 3.3 vs. 9.9 years, respectively, P 0.001). […] Median DFS was significantly worse in patients with high grade histology compared to those with low grade histology (16.9% vs. 65.7%, P 0.001). […] Histologic subtype and primary site were independent prognostic factors for curatively resected liposarcoma. A prognostic model for patients with liposarcoma clarified distinct groups of patients with good prognostic discrimination. […] In the multivariate Cox proportional model, histologic subtype and primary site were significant independent risk factors for DFS and OS. […] High-grade liposarcoma was significantly associated with a shorter DFS (hazard ratio [HR] 3.01; 95% confidence interval [CI], 1.82-4.97; P 0.001).

• #38 Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3398-y

  Grading, LS subtype, negative margins after surgery, metastases and tumour size are independently associated with disease-specific survival, and patients with local recurrence had lower survival rates. […] The survival rates were highly dependent on the grading, LS subtype, negative margins after surgery, metastases and tumour size. […] The existence of metastases and subtype were found to be major single prognostic factors affecting the survival rates. […] Patients with G2 liposarcoma showed significantly worse results in the overall survival than patients with G1 liposarcoma (p = 0.004; Hazard Ratio 8.1; 95%-CI 1.9-34.1) as well as patients with G3 liposarcoma compared to patients with G1 liposarcoma (p = 0.034; Hazard Ratio 4.7; 95%-CI 1.1-19.7). […] Local recurrence in the present study was associated with decreased survival. Patients with local recurrence showed 10- and 5-year survival rates of 86.2% and 49.0%, which was significantly lower than the survival of patients without recurrence (86.7% and 82.9% at 10 and 5 years).

• #39 Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3398-y

  Grading, LS subtype, negative margins after surgery, metastases and tumour size are independently associated with disease-specific survival, and patients with local recurrence had lower survival rates. […] The survival rates were highly dependent on the grading, LS subtype, negative margins after surgery, metastases and tumour size. […] The existence of metastases and subtype were found to be major single prognostic factors affecting the survival rates. […] Patients with G2 liposarcoma showed significantly worse results in the overall survival than patients with G1 liposarcoma (p = 0.004; Hazard Ratio 8.1; 95%-CI 1.9-34.1) as well as patients with G3 liposarcoma compared to patients with G1 liposarcoma (p = 0.034; Hazard Ratio 4.7; 95%-CI 1.1-19.7). […] Local recurrence in the present study was associated with decreased survival. Patients with local recurrence showed 10- and 5-year survival rates of 86.2% and 49.0%, which was significantly lower than the survival of patients without recurrence (86.7% and 82.9% at 10 and 5 years).

• #40 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The aim of this study was to identify prognostic indicators of survival in patients with locally recurrent soft tissue sarcoma (STS) through a long-term follow-up. […] The 5-year estimate of the PRS rate was 53.1% (95% CI: 44.361.2%) for the entire series. […] In a multivariate analysis, the significant prognostic indicators for PRS were histologic grade, tumour site, time to initial recurrence, the number of recurrences and the surgical margin status attained at the last resection. […] Complete surgical resection with microscopically clear margins is desirable in patients with locally recurrent STS. […] The total median survival times were 6.2 years after initial recurrence (95% CI: 4.47.6) and 1.5 years after the diagnosis of distant metastasis (95% CI: 0.932.17; Table 3). […] Patients who developed distant metastases had a 5-year survival of 17.0% (95% CI: 8.428.2) after the diagnosis of initial metastasis.

• #41 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The 5-year PRS rates were estimated to be 80.0% (95% CI: 55.192.0) for G1 and 44.5% (95% CI: 31.656.5) for G3 (P=0.003; Table 2). […] Concurrent metastasis at the time of initial recurrence was associated with significantly worse PRS compared with only localised disease (5-year PRS: 16.7% (2.741.3) vs 57.5% (39.769.6);P=0.0001). […] The surgical margin status attained by definitive resection of the recurrent tumour influenced PRS and survival after the final surgical treatment; microscopically negative margin status was associated with better PRS compared with positive margin status (5-year PRS: 56.2% (44.366.5) vs 50.8% (37.562.7)), although this survival distribution failed to reach statistical significance in the univariate analysis, and a borderline P-value was attained (P=0.059). […] Considering survival after the last resection, complete resection of the locally recurrent tumour with negative margins resulted in significantly more favourable survival for the entire group (5-year survival after last resection: 46.7% (35.257.5) vs 35.5% (23.447.8);P=0.01; Figure 2A, Table 4).

• #42 Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3398-y

  Grading, LS subtype, negative margins after surgery, metastases and tumour size are independently associated with disease-specific survival, and patients with local recurrence had lower survival rates. […] The survival rates were highly dependent on the grading, LS subtype, negative margins after surgery, metastases and tumour size. […] The existence of metastases and subtype were found to be major single prognostic factors affecting the survival rates. […] Patients with G2 liposarcoma showed significantly worse results in the overall survival than patients with G1 liposarcoma (p = 0.004; Hazard Ratio 8.1; 95%-CI 1.9-34.1) as well as patients with G3 liposarcoma compared to patients with G1 liposarcoma (p = 0.034; Hazard Ratio 4.7; 95%-CI 1.1-19.7). […] Local recurrence in the present study was associated with decreased survival. Patients with local recurrence showed 10- and 5-year survival rates of 86.2% and 49.0%, which was significantly lower than the survival of patients without recurrence (86.7% and 82.9% at 10 and 5 years).

• #43 Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3398-y

  In terms of the histologic status, 47.6% and 36.4% of patients with dedifferentiated and pleomorphic LS developed local recurrence in the present study. […] The median time to the development of the first metastasis was 27 months, and only a few cases had metastases ten years from surgery. […] Patients who developed distant metastasis after surgery showed 5- and 10-year survival rates of 45.6% and 21.9%, which were 96.8% and 93.0% for patients without metastases. […] Grading, the liposarcoma subtype, negative margins after surgery, metastases and tumour size are independently associated with disease-specific survival, and patients with local recurrence had lower survival rates.

• #44 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The 5-year PRS rates were estimated to be 80.0% (95% CI: 55.192.0) for G1 and 44.5% (95% CI: 31.656.5) for G3 (P=0.003; Table 2). […] Concurrent metastasis at the time of initial recurrence was associated with significantly worse PRS compared with only localised disease (5-year PRS: 16.7% (2.741.3) vs 57.5% (39.769.6);P=0.0001). […] The surgical margin status attained by definitive resection of the recurrent tumour influenced PRS and survival after the final surgical treatment; microscopically negative margin status was associated with better PRS compared with positive margin status (5-year PRS: 56.2% (44.366.5) vs 50.8% (37.562.7)), although this survival distribution failed to reach statistical significance in the univariate analysis, and a borderline P-value was attained (P=0.059). […] Considering survival after the last resection, complete resection of the locally recurrent tumour with negative margins resulted in significantly more favourable survival for the entire group (5-year survival after last resection: 46.7% (35.257.5) vs 35.5% (23.447.8);P=0.01; Figure 2A, Table 4).

• #45 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The aim of this study was to identify prognostic indicators of survival in patients with locally recurrent soft tissue sarcoma (STS) through a long-term follow-up. […] The 5-year estimate of the PRS rate was 53.1% (95% CI: 44.361.2%) for the entire series. […] In a multivariate analysis, the significant prognostic indicators for PRS were histologic grade, tumour site, time to initial recurrence, the number of recurrences and the surgical margin status attained at the last resection. […] Complete surgical resection with microscopically clear margins is desirable in patients with locally recurrent STS. […] The total median survival times were 6.2 years after initial recurrence (95% CI: 4.47.6) and 1.5 years after the diagnosis of distant metastasis (95% CI: 0.932.17; Table 3). […] Patients who developed distant metastases had a 5-year survival of 17.0% (95% CI: 8.428.2) after the diagnosis of initial metastasis.

• #46 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The aim of this study was to identify prognostic indicators of survival in patients with locally recurrent soft tissue sarcoma (STS) through a long-term follow-up. […] The 5-year estimate of the PRS rate was 53.1% (95% CI: 44.361.2%) for the entire series. […] In a multivariate analysis, the significant prognostic indicators for PRS were histologic grade, tumour site, time to initial recurrence, the number of recurrences and the surgical margin status attained at the last resection. […] Complete surgical resection with microscopically clear margins is desirable in patients with locally recurrent STS. […] The total median survival times were 6.2 years after initial recurrence (95% CI: 4.47.6) and 1.5 years after the diagnosis of distant metastasis (95% CI: 0.932.17; Table 3). […] Patients who developed distant metastases had a 5-year survival of 17.0% (95% CI: 8.428.2) after the diagnosis of initial metastasis.

• #47 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  Soft tissue tumours close to the surface of the body (superficial tumours) have a better prognosis than tumours that are growing deep within the body. […] Soft tissue sarcomas of the arms, legs or surface of the trunk of the body usually have a better prognosis than soft tissue sarcomas that start in other parts of the body. […] Some types of soft tissue sarcoma tend to have a worse prognosis, including malignant peripheral nerve sheath tumours (MPNSTs), leiomyosarcoma, desmoplastic small round cell tumours and epithelioid sarcoma. […] The lower the stage of soft tissue sarcoma at diagnosis, the better the prognosis. Stage 4 soft tissue sarcoma (metastatic soft tissue sarcoma) has a poor prognosis. […] If cancer cells are found in the margin (called a positive surgical margin), there is a poorer prognosis compared to when there are no cancer cells in the margin (called a negative surgical margin).

• #48 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The aim of this study was to identify prognostic indicators of survival in patients with locally recurrent soft tissue sarcoma (STS) through a long-term follow-up. […] The 5-year estimate of the PRS rate was 53.1% (95% CI: 44.361.2%) for the entire series. […] In a multivariate analysis, the significant prognostic indicators for PRS were histologic grade, tumour site, time to initial recurrence, the number of recurrences and the surgical margin status attained at the last resection. […] Complete surgical resection with microscopically clear margins is desirable in patients with locally recurrent STS. […] The total median survival times were 6.2 years after initial recurrence (95% CI: 4.47.6) and 1.5 years after the diagnosis of distant metastasis (95% CI: 0.932.17; Table 3). […] Patients who developed distant metastases had a 5-year survival of 17.0% (95% CI: 8.428.2) after the diagnosis of initial metastasis.

• #49 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The 5-year PRS rates were estimated to be 80.0% (95% CI: 55.192.0) for G1 and 44.5% (95% CI: 31.656.5) for G3 (P=0.003; Table 2). […] Concurrent metastasis at the time of initial recurrence was associated with significantly worse PRS compared with only localised disease (5-year PRS: 16.7% (2.741.3) vs 57.5% (39.769.6);P=0.0001). […] The surgical margin status attained by definitive resection of the recurrent tumour influenced PRS and survival after the final surgical treatment; microscopically negative margin status was associated with better PRS compared with positive margin status (5-year PRS: 56.2% (44.366.5) vs 50.8% (37.562.7)), although this survival distribution failed to reach statistical significance in the univariate analysis, and a borderline P-value was attained (P=0.059). […] Considering survival after the last resection, complete resection of the locally recurrent tumour with negative margins resulted in significantly more favourable survival for the entire group (5-year survival after last resection: 46.7% (35.257.5) vs 35.5% (23.447.8);P=0.01; Figure 2A, Table 4).

• #50 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The Cox model demonstrated that surgical attainment of negative margins at the last resection was associated with a significantly lower HR for death. The HR for negative compared with positive margin status after the last resection was 0.57 (95% CI: 0.340.94; P=0.026). […] Adverse prognostic features include early recurrence, truncal location and high-grade histology. […] The data from this study underscore the long-term benefit of negative margins achieved at the end of surgical treatment in patients with locally recurrent STS without distant metastases.

• #51 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  Soft tissue sarcoma that is completely removed by surgery has a much more favourable prognosis than soft tissue sarcoma that is not completely removed or if surgery cant be done. […] People with soft tissue sarcoma who are under the age of 50 tend to have a better prognosis than those over the age of 50.

• #52 Prognosis and survival for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/prognosis-and-survival

  Soft tissue sarcoma that is completely removed by surgery has a much more favourable prognosis than soft tissue sarcoma that is not completely removed or if surgery cant be done. […] People with soft tissue sarcoma who are under the age of 50 tend to have a better prognosis than those over the age of 50.

• #53 Outcome of patients with soft tissue sarcomas of the extremities and trunk treated by (neo)adjuvant intensity modulated radiation therapy with curative intent | Radiation Oncology | Full Text

  https://ro-journal.biomedcentral.com/articles/10.1186/s13014-023-02238-z

  86 patients were included in the analysis. The most common histological subtypes were undifferentiated pleomorphic high-grade sarcoma (UPS) (27) and liposarcoma (22). […] Female gender (HR 0.460 (0.217; 0.973)) and histology of liposarcomas compared to UPS proved to be significantly more favorable in terms of DFS (HR 0.327 (0.126; 0.852)). […] The median DFS was 48 months and the median DMFS was 51 months. […] A multivariable proportional hazard model for OS showed age (HR 1.042 (1.004; 1.080)) and male gender (HR 0.460 (0.217; 0.973)) as negative prognostic factors, with only age being statistically significant (p=0.028). For DFS, only gender and liposarcoma compared to UPS (HR 0.327 (0.126; 0.852), p=0.02) were significantly associated. […] Histology constitutes an important predictor for disease-free survival.

• #54 Outcome of patients with soft tissue sarcomas of the extremities and trunk treated by (neo)adjuvant intensity modulated radiation therapy with curative intent | Radiation Oncology | Full Text

  https://ro-journal.biomedcentral.com/articles/10.1186/s13014-023-02238-z

  86 patients were included in the analysis. The most common histological subtypes were undifferentiated pleomorphic high-grade sarcoma (UPS) (27) and liposarcoma (22). […] Female gender (HR 0.460 (0.217; 0.973)) and histology of liposarcomas compared to UPS proved to be significantly more favorable in terms of DFS (HR 0.327 (0.126; 0.852)). […] The median DFS was 48 months and the median DMFS was 51 months. […] A multivariable proportional hazard model for OS showed age (HR 1.042 (1.004; 1.080)) and male gender (HR 0.460 (0.217; 0.973)) as negative prognostic factors, with only age being statistically significant (p=0.028). For DFS, only gender and liposarcoma compared to UPS (HR 0.327 (0.126; 0.852), p=0.02) were significantly associated. […] Histology constitutes an important predictor for disease-free survival.

• #55 Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

  https://www.jcancer.org/v07p1174.htm

  Liposarcoma located in the trunk was a significantly poor prognostic factor for DFS (HR 1.80; 95% CI, 1.12-2.89; P = 0.015). […] The prognostic model separated patients into three risk groups with significantly different survival outcomes. The 5-year DFS rates for groups 1, 2, and 3 were 73.6%, 50.8%, and 19.2%, respectively. The 5-year OS rates for groups 1, 2, and 3 were 89.2%, 74.8%, and 41.4%, respectively.

• #56 Enhancing Liposarcoma Prognosis – A New Predictive Scoring System Inte | CMAR

  https://www.dovepress.com/enhancing-liposarcoma-prognosis–a-new-predictive-scoring-system-integ-peer-reviewed-fulltext-article-CMAR

  Liposarcomas are malignant soft tissue tumours with heterogeneous features and variable prognosis. […] The aim of this study is to analyse the clinical and histopathological features that can influence the prognosis of liposarcoma. […] Therefore, several clinical and histopathological features of liposarcomas, such as tumour location, mitotic index, and tumour necrosis can strongly predict the disease evolution. […] This study focuses on developing a new scoring system that considers histologic subtype, mitotic index, and tumour necrosis as indicators that could predict the risk of disease progression and overall survival in patients with liposarcoma. […] Diagnosing liposarcomas using this two-tiered system could be useful for providing personalized therapy, in order to avoid relapses, metastases and improve the diseases prognosis.

• #57 Enhancing Liposarcoma Prognosis – A New Predictive Scoring System Inte | CMAR

  https://www.dovepress.com/enhancing-liposarcoma-prognosis–a-new-predictive-scoring-system-integ-peer-reviewed-fulltext-article-CMAR

  Dedifferentiated and pleomorphic liposarcoma are associated with the most unfavorable prognosis, as patients develop metastases and have the worst survival rate. […] Well-differentiated and myxoid liposarcoma are usually associated with a lower metastatic potential and usually display locally aggressive behavior. […] Dedifferentiated liposarcoma is associated with an important metastatic potential, as this was the most frequent diagnosis of patients with progressive disease. […] A high mitotic index was associated with disease progression and poor survival during follow-up. […] Tumour necrosis is an important histologic factor associated with poor prognosis of liposarcoma. […] In our study group, tumour necrosis was statistically significant for disease progression and survival. […] We demonstrated that the only adverse prognosis factors are the histological subtype, higher mitotic index, and the presence of tumour necrosis for both PFS and overall survival. […] Classification of liposarcomas into low-grade and high-grade lesions is particularly important for a diligent prognostic evaluation and for achieving tailored therapeutic strategies.

• #58 Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response

  https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2022.251

  We also conducted integrative analysis to explore specific genomic markers correlated with response to pazopanib-based treatment in an attempt to identify biomarkers that could aid the therapeutic strategies. […] Patients with CDK4 amplification exhibited a poor response to pazopanib treatment, in which none of the nine partial responders had CDK4 amplification. […] A univariate Cox regression analysis revealed that CDK4 amplifications was predictive factors of poor PFS (hazard ratio [HR], 0.35; 95% CI, 0.14 to 0.86). […] Therefore, we hypothesize that alterations in CDK4 leading to its overexpression are associated with pazopanib resistance, and additional analyses are required to confirm and identify the underlying molecular mechanism.

• #59 Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response

  https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2022.251

  We also conducted integrative analysis to explore specific genomic markers correlated with response to pazopanib-based treatment in an attempt to identify biomarkers that could aid the therapeutic strategies. […] Patients with CDK4 amplification exhibited a poor response to pazopanib treatment, in which none of the nine partial responders had CDK4 amplification. […] A univariate Cox regression analysis revealed that CDK4 amplifications was predictive factors of poor PFS (hazard ratio [HR], 0.35; 95% CI, 0.14 to 0.86). […] Therefore, we hypothesize that alterations in CDK4 leading to its overexpression are associated with pazopanib resistance, and additional analyses are required to confirm and identify the underlying molecular mechanism.

• #60 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Pure myxoid liposarcoma is a relatively low-grade tumour which should be treated surgically with attempts to obtain clear margins of excision. […] Patients with 05% round cell component represent an intermediate-grade tumour with a higher risk of metastatic disease, whilst patients with 5% round cell component must be considered to have a high-grade tumour with a significantly increased risk of both local recurrence and metastases and should be treated with surgical excision with clear margins, radiotherapy, and possibly chemotherapy.

• #61 Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response

  https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2022.251

  Despite the heterogeneity, patients with advanced STS are generally treated in the same manner, mainly using doxorubicin- or ifosfamide-based regimens. […] However, despite several treatment possibilities, the prognosis of STS remains poor with a median overall survival (OS) of 12 months. […] Given the histological heterogeneity of STS, pazopanib has exhibited therapeutic activity against various subtypes except for liposarcoma in a stratified phase II trial. […] A subsequent phase III PALETTE trial was designed for patients with non-adipocytic STS who had not benefited from standard chemotherapy. […] The Cancer Genome Atlas (TCGA) Research Network has provided molecular insights into the major subtypes of STS. […] However, even though pazopanib is the only approved targeted agent for this disease, little is known about the genetic feature for response discrimination in STS.

• #62 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Pure myxoid liposarcoma is a relatively low-grade tumour which should be treated surgically with attempts to obtain clear margins of excision. […] Patients with 05% round cell component represent an intermediate-grade tumour with a higher risk of metastatic disease, whilst patients with 5% round cell component must be considered to have a high-grade tumour with a significantly increased risk of both local recurrence and metastases and should be treated with surgical excision with clear margins, radiotherapy, and possibly chemotherapy.

• #63 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Pure myxoid liposarcoma is a relatively low-grade tumour which should be treated surgically with attempts to obtain clear margins of excision. […] Patients with 05% round cell component represent an intermediate-grade tumour with a higher risk of metastatic disease, whilst patients with 5% round cell component must be considered to have a high-grade tumour with a significantly increased risk of both local recurrence and metastases and should be treated with surgical excision with clear margins, radiotherapy, and possibly chemotherapy.

• #64 Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3236386/

  Pure myxoid liposarcoma is a relatively low-grade tumour which should be treated surgically with attempts to obtain clear margins of excision. […] Patients with 05% round cell component represent an intermediate-grade tumour with a higher risk of metastatic disease, whilst patients with 5% round cell component must be considered to have a high-grade tumour with a significantly increased risk of both local recurrence and metastases and should be treated with surgical excision with clear margins, radiotherapy, and possibly chemotherapy.

• #65 Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response

  https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2022.251

  Despite the heterogeneity, patients with advanced STS are generally treated in the same manner, mainly using doxorubicin- or ifosfamide-based regimens. […] However, despite several treatment possibilities, the prognosis of STS remains poor with a median overall survival (OS) of 12 months. […] Given the histological heterogeneity of STS, pazopanib has exhibited therapeutic activity against various subtypes except for liposarcoma in a stratified phase II trial. […] A subsequent phase III PALETTE trial was designed for patients with non-adipocytic STS who had not benefited from standard chemotherapy. […] The Cancer Genome Atlas (TCGA) Research Network has provided molecular insights into the major subtypes of STS. […] However, even though pazopanib is the only approved targeted agent for this disease, little is known about the genetic feature for response discrimination in STS.

• #66 Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response

  https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2022.251

  Despite the heterogeneity, patients with advanced STS are generally treated in the same manner, mainly using doxorubicin- or ifosfamide-based regimens. […] However, despite several treatment possibilities, the prognosis of STS remains poor with a median overall survival (OS) of 12 months. […] Given the histological heterogeneity of STS, pazopanib has exhibited therapeutic activity against various subtypes except for liposarcoma in a stratified phase II trial. […] A subsequent phase III PALETTE trial was designed for patients with non-adipocytic STS who had not benefited from standard chemotherapy. […] The Cancer Genome Atlas (TCGA) Research Network has provided molecular insights into the major subtypes of STS. […] However, even though pazopanib is the only approved targeted agent for this disease, little is known about the genetic feature for response discrimination in STS.

• #67 Sarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Sarcoma

  Liposarcoma treatment usually consists of surgical resection, with chemotherapy considered depending on the aggressiveness of the sarcoma. Radiotherapy may also be used before or after surgical excision for liposarcoma. […] The AJCC has identified several factors that affect prognosis of bone sarcomas: […] For soft-tissue sarcomas other than GISTs, factors that affect prognosis include: […] For GISTs, the key factor that affects prognosis is: […] According to data published by the US National Cancer Institute (NCI), the overall 5-year survival for bone sarcomas is 66.9%. […] For soft-tissue sarcomas, the overall 5-year survival (irrespective of stage) is 64.5%, but survival is affected by many factors, including stage.

• #68 Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma | British Journal of Cancer

  https://www.nature.com/articles/bjc201421

  The Cox model demonstrated that surgical attainment of negative margins at the last resection was associated with a significantly lower HR for death. The HR for negative compared with positive margin status after the last resection was 0.57 (95% CI: 0.340.94; P=0.026). […] Adverse prognostic features include early recurrence, truncal location and high-grade histology. […] The data from this study underscore the long-term benefit of negative margins achieved at the end of surgical treatment in patients with locally recurrent STS without distant metastases.

Zobacz więcej